Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics announced promising clinical data for the combination of Zovegalisib, Atirmociclib, and aromatase inhibitors (AI) as a frontline triplet therapy for PIK3CA-mutated, HR+/HER2- metastatic breast cancer. The combination showed a 44% objective response rate (ORR) in heavily pre-treated patients, with favorable tolerance and manageabl…